Effects of sildenafil on lipid profile and glycemic control in patients with type 2 diabetes mellitus and metabolic syndrome

Haedar Abdulhafith Al-biati, Sajida Hussein Ismail, Ahmed Salih Sahib, Faris Abdul Kareem Kazaal, Salim Al-Rubaie

Abstract


Background: Insulin resistance impairs nitric oxide (NO) bioavailability; obesity promotes a state of metabolic syndrome and damages the vascular endothelium by altering lipid profile. Phosphodiesterase-5 (PDE-5) inhibitors restore NO signaling may improve metabolic parameters through a number of mechanisms. We hypothesized that daily administration of the PDE-5 inhibitor; sildenafil will improve fasting plasma glucose (FPG), triglyceride (TG) levels and body weight, in obese diabetic patients.

Methods: Totally, 25 obese diabetic male patients with metabolic syndrome treated with sildenafil 25 mg daily for 3 months. Body weight, FPG levels, and lipid profile were determined monthly.

Results: Treatment with sildenafil caused a reduction in fasting glucose levels, fasting TGs, cholesterol, low-density lipoprotein (LDL), very-LDL and increased high-density lipoprotein; body weight was significantly reduced.

Conclusion: We have provided the first evidence that sildenafil therapy improve glycemic control, lipid profile and body mass index in diabetic patients with metabolic syndrome.


Keywords


Sildenafil, Obesity, Type 2 diabetes mellitus, Metabolic syndrome

Full Text:

PDF

References


Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48.

Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011;18(8):629-39.

Lugnier C. PDE inhibitors: a new approach to treat metabolic syndrome? Curr Opin Pharmacol. 2011;11(6):698-706.

Karelis AD, Pasternyk SM, Messier L, St-Pierre DH, Lavoie JM, Garrel D, et al. Relationship between insulin sensitivity and the triglyceride-HDL-C ratio in overweight and obese postmenopausal women: a MONET study. Appl Physiol Nutr Metab. 2007;32(6):1089-96.

Ho JE, Arora P, Walford GA, Ghorbani A, Guanaga DP, Dhakal BP, et al. Effect of phosphodiesterase inhibition on insulin resistance in obese individuals. J Am Heart Assoc. 2014;3(5):e001001.

Onesi SO, Ignatius UE. Metabolic syndrome: performance of five different diagnostic criterias. Indian J Endocrinol Metab. 2014;18(4):496-501.

Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes. 2007;56(4):1025-33.

Tooke J. The association between insulin resistance and endotheliopathy. Diabetes Obes Metab. 1999;1 Suppl 1:

S17 22.

Polte T, Schröder H. Cyclic AMP mediates endothelial protection by nitric oxide. Biochem Biophys Res Commun. 1998;251(2):460-5.

Aboryag NB, Mahmoud AM, Ramadan SA. Sildenafil alleviate insulin sensitivity via attenuating oxidative stress and proinflammatory cytokine production in diabetic rats. Int J Pharm Bio Sci. 2013;4(4):B427-36.

Handa P, Tateya S, Rizzo NO, Cheng AM, Morgan-Stevenson V, Han CY, et al. Reduced vascular nitric oxide-cGMP signaling contributes to adipose tissue inflammation during high-fat feeding. Arterioscler Thromb Vasc Biol. 2011;31(12):2827-35.

Tateya S, Rizzo NO, Handa P, Cheng AM, Morgan-Stevenson V, Daum G, et al. Endothelial NO/cGMP/VASP signaling attenuates Kupffer cell activation and hepatic insulin resistance induced by high-fat feeding. Diabetes. 2011;60(11):2792-801.

Lasar D, Julius A, Fromme T, Klingenspor M. Browning attenuates murine white adipose tissue expansion during postnatal development. Biochim Biophys Acta. 2013;1831(5):960-8.

Mitschke MM, Hoffmann LS, Gnad T, Scholz D, Kruithoff K, Mayer P, et al. Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J. 2013;27(4):1621-30.